Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
TWYNEO is a topical cream combining tretinoin (a retinoid) and benzoyl peroxide for the treatment of acne. The formulation leverages retinoid activity to normalize skin cell turnover and reduce comedones, while benzoyl peroxide provides antimicrobial and anti-inflammatory benefits. This fixed-dose combination targets mild-to-moderate acne in a single application.
Product is at peak commercial stage with modest Medicare utilization; team size likely stabilized with focus on maximizing existing market penetration.
Retinoid
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TWYNEO offers limited career momentum; zero linked job openings signal a mature, stable commercial asset with small team footprint. Roles are predominantly sales and brand management-focused, with minimal growth trajectory into clinical or R&D domains.
Worked on TWYNEO at Mayne Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo